InterCure Ltd. (INCR) AI Stock Analysis

InterCure Ltd., headquartered in Herzliya, Israel, researches, cultivates, produces, markets, and distributes medical cannabis products globally. Established in 1994, the company offers dried cannabis inflorescences and cannabis extract blended with oils for domestic and international markets. In addition to its core medical cannabis operations across cultivation and distribution, InterCure maintains strategic investments in the biomed sector to advance healthcare innovations.

InterCure reported a 5-year revenue CAGR of 33.0% from FY2020 to FY2025. Annual revenue peaked in FY2022 at $388.7M before falling 8.5% in FY2023 and 32.8% in FY2024. In FY2025, revenue rebounded 13.1% to $270.2M, though gross margin contracted to 12.3% from 41.5% in FY2021. Operating margin was 2.5% in FY2025, improving from -28.1% in FY2024, but net income was -$35.7M. Over the trailing twelve months ended March 31, 2026, revenue was $243.1M with an operating margin of 0.0% and EPS of -$0.95. For the latest quarter, revenue grew 23.9% year-over-year, while quarterly earnings growth dropped 84.7%.

As of March 31, 2026, InterCure held $46.7M in cash and short-term investments against total debt of $183.0M, resulting in net debt of $136.3M. Total assets stood at $690.6M and shareholders' equity was $396.5M, yielding a debt-to-equity ratio of 0.46 and a current ratio of 1.48. In FY2025, the company generated operating cash flow of $16.8M and free cash flow of $13.3M, while spending $3.5M on capital expenditures. Share count declined 76.2% over 5 years.

At a last close of $4.57 on October 16, 2026, InterCure carries an enterprise value of $127.3M. The stock trades at a forward P/E of 6.2x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio is 0.7x compared to the peer median of 4.1x, and its EV-to-EBITDA multiple is 5.3x versus the peer median of 12.0x. Over the past year, INCR returned -40.6% while the S&P 500 (SPY) returned 16.8%. Over 5 years, the stock returned -87.1% compared to an 83.0% gain for SPY.

Wall Street analysts maintain a mean price target of $33.56 for InterCure, representing an implied upside of 634.4% from the last close of $4.57. Over the last four quarters, the company recorded 0 EPS beats. Forward earnings estimates imply a forward P/E multiple of 6.2x based on consensus expectations. Insider ownership stands at 38.2%, institutional ownership is 1.0%, and short interest as a percentage of the float is 0.0%.

This page is an AI-written research summary of InterCure Ltd. (INCR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: INCR income statement, INCR balance sheet, INCR key metrics, INCR chart. See the INCR stock overview for the latest quote and news.